Empagliflozin

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Empagliflozin and local guidelines before prescribing.

SGLT2 inhibitor

Mechanism

SGLT2 inhibitor increasing urinary glucose and sodium excretion.

Uses

Type 2 diabetes, heart failure, chronic kidney disease.

Dosing

4 more dose entries from the chapters
  • Examples: Dapagliflozin 10 mg, empagliflozin 10 mg (25 mg for extra glucose lowering), canagliflozin 100–300 mg, ertugliflozin - once daily.
    Endocrinology: Diabetes
  • Dapagliflozin / empagliflozin Type 2 first-line with metformin; HF; CKD | 10 mg once daily (empagliflozin 25 mg for extra glucose lowering). Genital infection, volume depletion, euglycaemic DKA. Sick day rules; omit around surgery.
    Endocrinology: Diabetes
  • Empagliflozin 10 mg daily (TA942) - eGFR 20–45 , or eGFR 45–90 with ACR 22.6 or more or type 2 diabetes.
    Renal: Chronic Kidney Disease
  • Empagliflozin 10 mg daily | CKD (TA942): eGFR 20–45, or 45–90 with ACR 22.6 or more or type 2 diabetes.
    Renal: Chronic Kidney Disease

Side effects

Genital infections, urinary infection, volume depletion, euglycaemic ketoacidosis, Fournier gangrene.

Interactions

Diuretics increase volume depletion; insulin and sulfonylureas increase hypoglycaemia risk.

Contraindications and cautions

Ketoacidosis history

Monitoring

eGFR, ketones if unwell

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Less glucose lowering at low eGFR; heart and kidney benefit continue

Overdose and reversal

Supportive

Special advice

Sick-day rules and pre-operative stopping; ketone check if unwell.

More from the textbook: uses, cautions and other points
Where it is discussed in the book